Open Access
Issue
J Extra Corpor Technol
Volume 50, Number 2, June 2018
Page(s) 77 - 82
DOI https://doi.org/10.1051/ject/201850077
Published online 15 June 2018
  1. Kirklin JK, Naftel DC, Pagani FD, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015;34:1495–504. [CrossRef] [PubMed] [Google Scholar]
  2. Harvey L, Holley CT, John R Gastrointestinal bleed after left ventricular assist device implantation: Incidence, management, and prevention. Ann Cardiothorac Surg. 2014;3:475–9. [PubMed] [Google Scholar]
  3. Davis ME, Haglund NA, Tricarico NM, et al. Development of acquired von Willebrand syndrome during short-term micro axial pump support: Implications for bleeding in a patient bridged to a long-term continuous-flow left ventricular assist device. ASAIO J. 2014;60:355–7. [CrossRef] [PubMed] [Google Scholar]
  4. Klovaite J, Gustafsson F, Mortensen SA, et al. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol. 2009;53:2162–7. [CrossRef] [PubMed] [Google Scholar]
  5. Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010;56:1207–13. [CrossRef] [PubMed] [Google Scholar]
  6. Crow S, Chen D, Milano C, et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg. 2010;90:1263–9. [CrossRef] [PubMed] [Google Scholar]
  7. Geisen U, Heilmann C, Beyersdorf F, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg. 2008;33:679–84. [CrossRef] [PubMed] [Google Scholar]
  8. Meyer AL, Malehsa D, Budde U, et al. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail. 2014;2:141–5. [CrossRef] [PubMed] [Google Scholar]
  9. Heilmann C, Geisen U, Beyersdorf F, et al. Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart. J Thromb Haemost. 2010;103:962–7. [CrossRef] [PubMed] [Google Scholar]
  10. Flierl U, Tongers J, Berliner D, et al. Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. PLoS One. 2017;12:e0183193. [CrossRef] [PubMed] [Google Scholar]
  11. Kalbhenn J, Schmidt R, Nakamura L, et al. Early diagnosis of acquired von Willebrand Syndrome (AVWS) is elementary for clinical practice in patients treated with ECMO therapy. J Atheroscler Thromb. 2015;22:265–71. [CrossRef] [PubMed] [Google Scholar]
  12. Reich HJ, Morgan J, Arabia F, et al. Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart. J Thromb Haemost. 2017;15:1620–4. [CrossRef] [PubMed] [Google Scholar]
  13. Birschmann I, Dittrich M, Eller T, et al. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. J Heart Lung Transplant. 2014;33:80–7. [CrossRef] [PubMed] [Google Scholar]
  14. Bartoli CR, Kang J, Zhang D, et al. Left ventricular assist device design reduces von Willebrand factor degradation: A comparative study between the HeartMate II and the EVAHEART left ventricular assist system. Ann Thorac Surg. 2017;103:1239–44. [CrossRef] [PubMed] [Google Scholar]
  15. Netuka I, Kvasnicka T, Kvasnicka J, et al. Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure. J Heart Lung Transplant. 2016;35:860–7. [CrossRef] [PubMed] [Google Scholar]
  16. Rodeghiero F, Castaman G and Dini E Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69:454–9. [CrossRef] [PubMed] [Google Scholar]
  17. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4:2103–14. [CrossRef] [PubMed] [Google Scholar]
  18. Shida Y BC, Mewburn J, Sponagle K, et al. Impact of ADAMTS13-mediated regulation of von Willebrand factor multimer profile on hemostasis and VWF clearance. J Thromb Haemost. 2013;11(Suppl 2):288. [Google Scholar]
  19. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: A multiethnic study. J Pediatr. 1993;123:893–8. [CrossRef] [PubMed] [Google Scholar]
  20. Pate GE, Chandavimol M, Naiman SC, et al. Heyde's syndrome: A review. J Heart Valve Dis. 2004;13:701–12. [PubMed] [Google Scholar]
  21. Blackshear JL, Wysokinska EM, Safford RE, et al. Shear stress-associated acquired von Willebrand syndrome in patients with mitral regurgitation. J Thromb Haemost. 2014;12:1966–74. [CrossRef] [PubMed] [Google Scholar]
  22. Shimizu M, Masai H and Miwa Y Occult gastrointestinal bleeding due to acquired von Willebrand syndrome in a patient with hypertrophic obstructive cardiomyopathy. Intern Med. 2007;46:481–5. [CrossRef] [PubMed] [Google Scholar]
  23. Zheng XL Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost. 2013;11(Suppl 1):11–23. [CrossRef] [PubMed] [Google Scholar]
  24. Nascimbene A, Neelamegham S, Frazier OH, et al. Acquired von Willebrand syndrome associated with left ventricular assist device. Blood. 2016;127:3133–41. [CrossRef] [PubMed] [Google Scholar]
  25. Susen S, Rauch A, Van Belle E, et al. Circulatory support devices: Fundamental aspects and clinical management of bleeding and thrombosis. J Thromb Haemost. 2015;13:1757–67. [CrossRef] [PubMed] [Google Scholar]
  26. Jilma-Stohlawetz P, Quehenberger P, Schima H, et al. Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent. Thromb Res. 2016;137:196–201. [CrossRef] [PubMed] [Google Scholar]
  27. Tsai HM von Willebrand factor, shear stress, and ADAMTS13 in hemostasis and thrombosis. ASAIO J. 2012;58:163–9. [CrossRef] [PubMed] [Google Scholar]
  28. Bartoli CR, Kang J, Restle DJ, et al. Inhibition of ADAMTS-13 by doxycycline reduces von Willebrand factor degradation during supraphysiological shear stress: Therapeutic implications for left ventricular assist device-associated bleeding. JACC Heart Fail. 2015;3:860–9. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.